CAR-T therapy for autoimmune diseases: trial pulled before start
NCT ID NCT06548620
First seen Feb 03, 2026 · Last updated May 02, 2026 · Updated 11 times
Summary
This early-phase trial aimed to test a CD19-targeted CAR-T cell therapy (RD06-04) in people with autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The goal was to see if the treatment was safe and could reduce disease activity. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 461499, China
Conditions
Explore the condition pages connected to this study.